NCT04798001View on ClinicalTrials.gov

Safety and Immunogenicity of an Intranasal RSV Vaccine Expressing SARS-CoV-2 Spike Protein (COVID-19 Vaccine) in Adults

PHASE1UnknownINTERVENTIONAL
Enrollment

130

Participants

Timeline

Start Date

April 12, 2021

Primary Completion Date

October 31, 2022

Study Completion Date

October 31, 2022

Conditions
Covid19
Interventions
BIOLOGICAL

Investigational vaccine against SARS-CoV-2 [MV-014-212] Dosage 1, Single Dose, Intranasal Drops

Single intranasal dose on Day 1, by intranasal drops

BIOLOGICAL

Investigational vaccine against SARS-CoV-2 [MV-014-212] Dosage 2, Single Dose, Intranasal Drops

Single intranasal dose on Day 1, by intranasal drops

BIOLOGICAL

Investigational vaccine against SARS-CoV-2 [MV-014-212] Dosage 3, Single Dose, Intranasal Drops

Single intranasal dose on Day 1, by intranasal drops

BIOLOGICAL

Investigational vaccine against SARS-CoV-2 [MV-014-212] Dosage 3, Two Doses, Intranasal Drops

Intranasal dose on Day 1 by intranasal drops. Followed by a second, identical dose on Day 36 by intranasal drops

BIOLOGICAL

Investigational vaccine against SARS-CoV-2 [MV-014-212] Dosage 3, Single Dose, Intranasal Spray

Single intranasal dose on Day 1, by intranasal spray

Trial Locations (2)

27612

RECRUITING

Wake Research, Raleigh

66219

RECRUITING

Johnson County Clin-Trials, Lenexa

Sponsors
All Listed Sponsors
lead

Meissa Vaccines, Inc.

INDUSTRY

NCT04798001 - Safety and Immunogenicity of an Intranasal RSV Vaccine Expressing SARS-CoV-2 Spike Protein (COVID-19 Vaccine) in Adults | Biotech Hunter | Biotech Hunter